These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 77876)

  • 1. Idiotype-specific transplantation resistance to MOPC-315: abrogation by post-immunization thymectomy.
    Daley MJ; Gebel HM; Lynch RG
    J Immunol; 1978 May; 120(5):1620-4. PubMed ID: 77876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of myeloma growth in vitro by idiotype-specific T lymphocytes.
    Flood PM; Philipps C; Taupier MA; Schreiber H
    J Immunol; 1980 Jan; 124(1):424-30. PubMed ID: 6965296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoregulation of murine myeloma: isologous immunization with M315 induces idiotype-specific T cells that suppress IgA secretion by MOPC-315 cells in vivo.
    Rohrer JW; Odermatt B; Lynch RG
    J Immunol; 1979 May; 122(5):2011-9. PubMed ID: 87450
    [No Abstract]   [Full Text] [Related]  

  • 4. The effect of plasmacytomas on serum immunoglobulin levels of BALB/c mice.
    Fenton MR; Havas HF
    J Immunol; 1975 Feb; 114(2 pt 2):793-801. PubMed ID: 1089719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of immune response to sheep red blood cells on plasmacytoma MOPC 104 E.
    Ghanta VK; Hiramoto NS; Hiramoto RN
    Cancer Res; 1981 Jun; 41(6):2197-9. PubMed ID: 7237419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy.
    Adler A; Altbaum I
    J Natl Cancer Inst; 1982 Jun; 68(6):963-9. PubMed ID: 6953275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. II. Enhancement of in vitro cell-mediated cytotoxicity by combined chemotherapy-immunotherapy.
    Adler A; Keisari Y; Ofir R
    J Natl Cancer Inst; 1985 Feb; 74(2):429-36. PubMed ID: 3856051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idiotype-specific T cell suppression of light chain mRNA expression in MOPC-315 cells is accompanied by a posttranscriptional inhibition of heavy chain expression.
    Milburn GL; Parslow TG; Goldenberg C; Granner DK; Lynch RG
    J Mol Cell Immunol; 1984; 1(2):115-23. PubMed ID: 6242851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection against MOPC-315 plasmacytoma by immunization with C-type particle preparations.
    Kleinman R; Dray S
    Cancer Res; 1978 Jan; 38(1):223-5. PubMed ID: 201375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regression of MOPC 104E plasmacytoma with monoclonal anti-idiotype antibodies.
    Kodama K; Ghanta VK; Hiramoto NS; Hiramoto RN
    J Biol Response Mod; 1989 Aug; 8(4):385-96. PubMed ID: 2754437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigen-specific regulation of myeloma cell differentiation in vivo by carrier-specific T cell factors and macrophages.
    Rohrer JW; Lynch RG
    J Immunol; 1978 Sep; 121(3):1066-74. PubMed ID: 80422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of subcutaneously administered 2,6,10,14-tetramethylpentadecane on plasmacytoma growth.
    Platica M; Bojko C; Steiner G; Hollander VP
    Cancer Res; 1980 Jul; 40(7):2229-33. PubMed ID: 6248200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Participation of the humoral immune system in the myeloma-specific transplantation resistance.
    Bridges SH
    J Immunol; 1978 Aug; 121(2):479-83. PubMed ID: 681744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface.
    Nio Y; Hirahara N; Minari Y; Iguchi C; Yamasawa K; Toga T; Tamura K
    Anticancer Res; 2000; 20(5A):3293-9. PubMed ID: 11062756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoregulation of localized and disseminated murine myeloma: antigen-specific regulation of MOPC-315 stem cell proliferation and secretory cell differentiation.
    Rohrer JW; Lynch RG
    J Immunol; 1979 Sep; 123(3):1083-7. PubMed ID: 89159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloma-induced immunosuppression: a multistep mechanism.
    Katzmann JA
    J Immunol; 1978 Oct; 121(4):1405-9. PubMed ID: 701801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transfer of idiotypic protein primed allogeneic marrow grafts elicits potent graft-versus-myeloma effects in mice.
    Zeis M; Steinmann J; Petrela E; Hartung G; Schmitz N; Uharek L
    Bone Marrow Transplant; 2001 Feb; 27(3):279-85. PubMed ID: 11277175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunity against MOPC 104E plasmacytoma: effects of tumor size and time post therapy on in vivo tumor immunity.
    Lubet RA; Carlson DE
    J Natl Cancer Inst; 1978 May; 60(5):1107-11. PubMed ID: 642029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Thymectomy and splenectomy of adult mice have no influence on the level of suppressor activity of T-lymphocytes specific to antigens of H-2 complex].
    Kronin VV; Anosova NG
    Biull Eksp Biol Med; 1992 Apr; 113(4):392-5. PubMed ID: 1391898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dynamics of the immunodepressive and antitumor activity of adriamycin].
    Vereina TL; Turishchev VE; Gavrilova AD; Matveev AB
    Farmakol Toksikol; 1986; 49(1):73-5. PubMed ID: 3948992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.